{"schema_version":"secwatch.filing_event.v1","accession":"0001798749-24-000029","form_type":"8-K","ticker":"JBIO","cik":"0001798749","company_name":"Jade Biosciences, Inc.","filed_at":"2024-05-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:20.164324+00:00","generated_at":"2026-06-02T02:36:24.503281+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Aerovate reports Q1 2024 net loss $23.2M; cash $99.3M; Phase 2b topline data expected June 2024","bullets":["Net loss of $23.2M for Q1 2024 vs $16.5M in Q1 2023; R&D expenses $20.1M, G&A $4.5M.","Cash, equivalents and short-term investments $99.3M at March 31, 2024; raised net $23.6M via ATM in April.","Topline data from Phase 2b portion of IMPAHCT trial of AV-101 in PAH expected in June 2024.","Enrollment continues in Phase 3 portion of IMPAHCT; over 120 sites in 20+ countries.","Cash runway into 2026 based on current operating plan."],"urls":{"canonical":"https://secwatch.observer/filing/0001798749-24-000029","json":"https://secwatch.observer/filing/0001798749-24-000029.json","markdown":"https://secwatch.observer/filing/0001798749-24-000029.md","text":"https://secwatch.observer/filing/0001798749-24-000029.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1798749/000179874924000029/0001798749-24-000029-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1798749/000179874924000029/tmb-20240513x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T02:36:24.503281+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"9b171013b7a300d0934a0efc95f485003c81fbff","claim":"Jade Biosciences, Inc. reported quarter ended March 31, 2024 results: net income Net loss for the quarter ended March 31, 2024 was $23.2 million as compared to $16.5 million for the quarter ended March.","evidence_excerpt":"Net loss for the quarter ended March 31, 2024 was $23.2 million as compared to $16.5 million for the quarter ended March 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1798749/000179874924000029/0001798749-24-000029-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"quarter ended March 31, 2024"},{"label":"Net income","value":"Net loss for the quarter ended March 31, 2024 was $23.2 million as compared to $16.5 million for the quarter ended March"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}